A Registered Cohort Study on Spastic Paraplegia

The aim of this study is to determine the clinical spectrum and natural progression of Hereditary Spastic Paraplegias(HSP) and related disorders in a prospective multicenter natural history study, to assess the clinical, genetic and epigenetic features of patients with Spastic Paraplegias to optimize clinicalmanagement..

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Spastic Paraplegia Nervous System Diseases Neurologic Manifestations Paralysis Paraplegia Pathological Conditions, Signs and Symptoms Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

First Affiliated Hospital Fujian Medical University

Fuzhou, China

Location status: Recruiting

Location contact

Ning Wang

SUB_INVESTIGATOR

Wan-Jian Chen, MD, PhD

CONTACT

[email protected]

Wan-Jin Chen

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with the clinical diagnosis of spastic paraplegia
Clinical diagnosis of patients with spastic paraplegia
Unrelated healthy controls

Exclusion criteria

Decline to participate.
There are serious interferences with individual participation and adherence to the research protocol, including but not limited to neurological, psychological, and/or medical conditions.

Treatment and study plan

Primary outcomes

Spastic Paraplegia Rating Scale (SPRS)

Time frame: 6 months

Disease severity will be assessed by application of the Spastic Paraplegia Rating Scale (SPRS), a clinical rating scale measuring disease severity in Hereditary Spastic Paraplegia (Schule et al. Neurology 2006). The SPRS contains 13 items, each ranging from 0 to 4 points. The total score is calculated as the sum of all items, yielding a range for the total score between 0 and 52. Hereby, higher SPRS total scores indicate more severe disease.

Study contacts

Contact information is provided by the study sponsor or research team.

Wan-Jin Chen, MD,PhD

CONTACT

[email protected]

+1386061359 ext. +1386061359

Yi Lin, MD,PhD

CONTACT

[email protected]

+13615039153

Sponsors and collaborators

Lead sponsor

Wan-Jin Chen

Other

Registry information

Important dates

Study start: 2019
Primary completion: 2039
Study completion: 2049
First posted: Jul 5, 2019
Registry last updated: Jan 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting